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Abstract
Prediction of the future trajectory of a disease is an important challenge for personalized
medicine and population health management. However, many complex chronic diseases
exhibit large degrees of heterogeneity, and furthermore there is not always a single readily
available biomarker to quantify disease severity. Even when such a clinical variable exists,
there are often additional related biomarkers routinely measured for patients that may
better inform the predictions of their future disease state. To this end, we propose a novel
probabilistic generative model for multivariate longitudinal data that captures dependencies
between multivariate trajectories. We use a Gaussian process based regression model for
each individual trajectory, and build off ideas from latent class models to induce dependence
between their mean functions. We fit our method using a scalable variational inference
algorithm to a large dataset of longitudinal electronic patient health records, and find that
it improves dynamic predictions compared to a recent state of the art method. Our local
accountable care organization then uses the model predictions during chart reviews of high
risk patients with chronic kidney disease.
1. Introduction
The ability of healthcare organizations to make accurate predictions about individuals’ future
health is becomingly increasingly important with the adoption of accountable care and
alternative payment models (CMS (2016)). In particular, management of complex, chronic
diseases such as cardiovascular disease, diabetes, and chronic kidney disease is especially
difficult, because selection of optimal therapy may require integration of multiple conditions
and risk factors that are each considered in isolation under current approaches to care.
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Additionally, individuals with multiple chronic conditions are among both the most expensive
and highest utilizers of healthcare services (Johnson and et al. (2015)).
Accountable care organizations (ACOs) are institutions that aim to link provider reim-
bursement with quality metrics and reductions in total cost of healthcare services to a specific
population of patients. These organizations need personalized prediction tools capable of
flagging specific patients in their populations at the highest risk of having poor outcomes
(Parikh et al. (2016)). Much of the data required to develop such tools are already being
routinely collected, due to the recent widespread adoption of Electronic Health Records
(EHRs). However, in order to be clinically relevant the prediction methods will need to be
flexible enough to accommodate the inherent limitations of operational EHR data (Hersh
and et al (2013)), dynamically update predictions as more information is collected, and scale
seamlessly to the massive size of modern health records.
Prediction of future disease trajectory is a challenging problem. One difficulty is the
many underlying sources of variability that can drive the different potential manifestations of
the disease. For instance, the underlying biological mechanisms of the disease can give rise
to latent disease subtypes, or groups of individuals with shared characteristics (Saria and
Goldenberg (2015)). For most complicated diseases, there are no clear definitions of subtypes,
so this must be inferred from the data. In addition, there are individual-specific sources
of variability that may not be directly observed, such as behavioral factors, environmental
conditions, or temporary infections. Another challenge is the fact that observations are
irregularly sampled, asynchronous, and episodic, precluding the use of many time series
methods developed for data regularly sampled at discrete time intervals. The large degree
of missing data, especially when modeling multivariate longitudinal data, also presents
complications. The task is made even more difficult when the primary data source is the
EHR rather than a curated registry, as even defining a relevant cohort of patients to model
can take extensive review by a clinical expert.
We collaborated with Duke Connected Care, the ACO affiliated with the Duke University
Health System, to create models to predict disease progression in chronic kidney disease
(CKD). CKD is characterized by a slow and typically symptomless loss of kidney function over
time, resulting in complications that can cause poor health, premature death, increased health
service utilization, and excess economic costs. A person’s estimated glomerular filtration rate
(eGFR) is an approximation of overall kidney function and is calculated using a common
clinical laboratory test (serum creatinine or cystatin C) and demographic information (age,
sex and race) (Levey and et al. (2009)). Impairment of a person’s eGRF is used to define
and stage CKD. In addition, a number of other routinely measured laboratory values may
be used to help detect abnormal or declining kidney function.
Providing optimal care for CKD patients is a challenging problem for healthcare providers.
Even though CKD can be easily identified using simple, eGFR-based laboratory criteria,
it is often not recognized (Szczech et al. (2014), Tuot et al. (2011)). Predicting which
patients with recognized CKD will progress to kidney failure (requiring dialysis or kidney
transplantation), or suffer from other complications such as early death from heart attack
or stroke, is a difficult task (Mendelssohn et al. (2011)). Additionally, oftentimes providers
fail to prescribe appropriate preventive treatment to slow disease progression or address
complications (Smart et al. (2014)).
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Figure 1: Clinical course of a patient who experienced a rapid progression of CKD as well as
other serious health events. Y-axis denotes estimated glomerular filtration rate
(eGFR), an estimate of overall kidney function (60-100 is normal, <60 indicates
clinically significant kidney disease). X-axis denotes patient age, in years. Markers
denote adverse events and health system use.
These traits make CKD an ideal condition to develop disease progression models that can
be used in high-impact care management programs. The difficulties with CKD care are best
explained with a representative clinical case, illustrated in Figure 1. A 47 year-old man makes
first contact with the health system with normal kidney function, although he possesses
several risk factors for developing CKD in the future. He receives sufficient medical care over
the next few years to detect that his kidney function is rapidly deteriorating (normal annual
rate of kidney function loss at his age is only about 1-2%). Due to other more pronounced
medical conditions, his kidney disease goes unnoticed and he does not receive any treatment
to slow progression to total kidney failure. He is finally referred to a kidney specialist
at age 52, more than a year after his kidney function has fallen below the recommended
referral threshold. There is now not enough time to make advanced preparations for kidney
failure, such as pre-emptive kidney transplantation or at-home dialysis, and kidney failure is
inevitable. Less than 90 days from the first specialist appointment, he requires hospitalization
for emergency dialysis initiation, a traumatizing procedure that also makes him among the
most expensive class of patient to treat (Johnson and et al. (2015)). He suffers multiple
cardiovascular complications from kidney failure while on dialysis over the next decade,
ultimately dying at age 63. This patient story is riddled with missed opportunities that
could have been acted upon by a care management program that uses accurate predictions
from machine learning models for disease progression.
Our aim in this work is to develop broadly applicable statistical methods that flexibly
model multivariate longitudinal data in order to jointly predict future disease trajectories
with other related variables, such as patient symptoms or relevant laboratory values. To
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accomplish this, we utilize a hierarchical latent variable model that captures dependencies
between multivariate longitudinal trajectories. Our model uses a Gaussian process (GP) with
a highly structured mean function to model each longitudinal variable for each individual.
The mean functions for the GPs are made dependent through shared latent variables. Using
our model, we study a large cohort of patients with CKD from the Duke University Health
System EHR and make predictions about the future trajectory of their disease severity, as
measured by eGFR, along with five other commonly recorded laboratory values that are
known to be affected by CKD. Our inference algorithm scales well to the large dataset, and
makes accurate predictions that outperform a state-of-the-art baseline.
2. Related Work
Within the medical literature, the vast majority of predictive models are cross-sectional and
only consider features at or up until the current time to predict outcomes at a fixed point
in the future. Typically, these models only attempt to explain variability in the outcome
of interest by conditioning on baseline covariates. This precludes the ability to generate
dynamic individualized predictions, making them difficult to use for medical decision making
in practice. For instance, Tangri and et al. (2011) is a commonly referenced Cox proportional
hazards model for predicting time to kidney failure.
Within the statistics and machine learning communities, Markov models of many varieties
are frequently used to generate dynamic predictions, e.g. autoregressive models, HMMs, and
state space models (Murphy (2012)). However, these methods are generally only applicable in
settings with discrete, regularly-spaced observation times, and in most applications the data
consists of a single set of multivariate time series (e.g. financial returns), not a large collection
of sparsely sampled multivariate time series (in our setting, disease or lab trajectories). GPs
have been commonly been used in settings with continuous time observations, see e.g. (Shi
et al. (2005)) for a thorough overview. Since they are prior distributions over functions, they
are a natural modeling choice for disease trajectories, however, accurate forecasts for GPs
require careful specification of the mean functions (Roberts and et al. (2013)).
There are several related works that tackle the problem of dynamic predictions with
medical applications in mind. (Rizopoulos (2011)) construct joint models with a focus on
updating dynamic predictions about time to death as more values of a longitudinal biomarker
are observed. They also account for individual heterogeneity using random effects. Related
work on joint modeling (Proust-Lima and et al. (2014)) use a mixture model to address
heterogeneity. Although a few works from this joint modeling literature address multivariate
data, typically the only dependency among variables is simplistic, coming from a shared
vector of random effects. Most similar to our work is (Schulam and Saria (2015)), who present
a model for a univariate marker of disease trajectory using a GP with highly structured
mean function.
There has been much recent interest in machine learning in modeling EHRs and other
types of healthcare data. For instance, (Lian and et al. (2015)) use hierarchical point processes
to predict hospital admissions, and (Ranganath and et al. (2015)) develop a dynamic factor
model to learn relationships between diseases and predict future diagnosis codes. Some
related papers use multitask GPs to model multivariate, longitudinal clinical data (Durichen
and et al. (2015), Ghassemi and et al. (2015)). However, these works use independently
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trained models for each patient and do not hierarchically share information across patients.
This worked well in their examples where there were a large number of observations for each
patient and little missing data, but would not work well with our much sparser EHR data.
Closest to our work in the application is (Perotte and et al. (2015)), who predict time of
progression from CKD stage 3 to stage 4. Although they use a standard Kalman filter to
model multivariate laboratory data, this is not the focus of their work and will not be as
flexible as our GP-based models. Finally, Futoma et al. (2016) present a method for jointly
modeling CKD disease trajectory with adverse events.
3. Proposed Multivariate Disease Trajectory Model
Our proposed hierarchical latent variable model jointly models each patient’s multivariate
longitudinal data by using a GP for each individual variable, with shared latent variables
inducing dependence between the mean functions. Note that our model reduces to the
method presented in (Schulam and Saria (2015)) in the univariate setting.
Let ~yi(t) = (yi1(t), . . . , yiP (t))> ∈ RP denote the P−dimensional trajectory of measure-
ments for individual i, and let ~yip = {yip(tipj)}nipj=1 be the nip observations for variable p at
times tipj for this individual. Let ci, ~zi, ~bi, and ~fi be latent variables specific to individual i, to
be defined subsequently. We will assume for each person that the longitudinal variables are con-
ditionally independent given these latent variables: p(~yi|ci, ~zi, ~bi, ~fi) =
∏P
p=1 p( ~yip|ci, ~zi, ~bi, ~fi).
For each longitudinal variable, we propose the following generative model:
yip(t) ∼ N(µip(t), σ2p) (1)
µip(t) ∼ GP(Λ(p)xi + Φz(t)>β(p)zip + Φl(t)>bip,Kp) (2)
Kp(t, t
′) = a2pexp{−l−1p |t− t′|} (3)
zip|ci ∼ Multinomial(Ψ(p)ci ) (4)
with common priors across all P variables:
ci ∼ Multinomial(pii), piig = e
w>g xi∑G
g′=1 e
w>
g′xi
(5)
~bi = (bi1, . . . , biP )
> ∼ N(0,Σb). (6)
The first term in the mean function (2) is a population-level fixed effect that uses observed
baseline covariates xi ∈ Rq, e.g. gender and race, to determine a population-level intercept
for each lab, with Λ(p) ∈ Rq a coefficient vector. This can easily be extended to accommodate
more flexible fixed effects, e.g. a fixed intercept and slope.
The second term in (2) is a subpopulation component, where it is assumed individual i’s
trajectory for variable p belongs to a latent subpopulation, denoted zip ∈ {1, . . . , Gp}. Each
subpopulation is associated with a unique trajectory; in particular, Φz(t) ∈ Rdz is a fixed
B-spline basis expansion of time (for simplicity, assumed to be the same for each variable
with eight interior knots evenly spaced in time) with β(p)g ∈ Rdz the coefficient vector for
subpopulation g and variable p.
The prior for each zip in (4) depends on the individual’s “global” cluster ci ∈ {1, . . . , G}.
Drawing on ideas from latent structure analysis for multivariate categorical data (Lazarsfeld
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and Henry (1968)), the ci induce dependence among the P trajectory-specific clusters zip, as
they have conditionally independent multinomial priors. Each of the G columns Ψ(p)g in the
matrix Ψ(p) ∈ RGp×G defines a distribution over the Gp values that zip can take. The ci then
has a multinomial logistic regression prior in (5) that depends on the baseline covariates xi,
where {wg}Gg=1 are regression coefficients with w1 ≡ 0 for identifiability.
The third term in (3) is a random effects component, allowing for individual-specific long-
term deviations in trajectory that are learned dynamically as more data becomes available.
In practice Φl(t) ∈ Rdl is a linear expansion of time with dl = 2, so that bip ∈ Rdl is a random
slope and intercept vector for patient i. The overall vector ~bi has a multivariate normal prior
distribution in (6), making the random effects dependent across labs.
Finally, Kp(t, t′) = a2pexp{−l−1p |t − t′|} is the Ornstein-Uhlenbeck (OU) covariance
function for the GP each variable, with parameters ap, lp. This kernel is well-suited for
modeling transient deviations from the mean function, as it is mean-reverting and has
no long-range dependence between deviations. We can rewrite (2) as µip(t) = Λ(p)xi +
Φz(t)
>βzip + Φl(t)>bip + fip(t), where fip(t) ∼ GP(0,Kp), so that we can explicitly represent
the short-term deviations fip from the GP in order to learn them during inference.
4. Inference
The computational problem associated with fitting our model is estimation of the posterior
distribution of latent variables and model parameters given the observed data. As is common
with complex probabilistic generative models, exact computation of the posterior is intractable
and requires approximation to compute. To this end, we develop a mean field variational
inference [Jordan et al., 1999] algorithm to find an approximation to the posterior.
Variational inference converts the task of posterior inference into an optimization problem
of finding a distribution q in some approximating family of distributions that is close in KL
divergence to the true posterior. The problem is equivalent to maximizing what is known as
the evidence lower bound (ELBO) [Bishop, 2006]:
L(q) = Eq[log p(y, z, b, f, c,Θ)− log q(z, b, f, c,Θ)], (7)
which forms a lower bound on the marginal likelihood p(y) of our model.
Variational Approximation
The model parameters to be learned are Θ =
{{Λ(p), β(p),Ψ(p), ap, lp, σ2p}Pp=1,W,Σb}, and
the local latent variables specific to each person are their global cluster assignment ci,
subpopulation assignments zip, random effects ~bi and structured noise functions fip. The
joint distribution for our model can be expressed as:
p(y, z, b, f, c,Θ) = p(Θ)
N∏
i=1
p(bi|Θ)p(ci|Θ)
P∏
p=1
p( ~yip|zip, bip, fip,Θ)p(zip|ci,Θ)p(fip|Θ) (8)
We make the mean field assumption for the variational distribution, which assumes that
in the approximate posterior q, all the latent variables are independent. This implies that
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q(z, b, f, v,Θ) = q(Θ)
∏N
i=1 qi(ci, zi, bi, fi), where:
qi(ci, zi, bi, fi) = qi(ci|νci)qi(bi|µbi ,Σbi)
P∏
p=1
qi(zip|νzip)qi(fip|µfip ,Σfip) (9)
The assumed variational distributions for each latent variable are in the same family as their
prior distribution, i.e. ci and the zip are multinomials, bi is multivariate normal. For the fip
we use a full multivariate normal evaluated at all times at which variable p is observed for
person i. In order to evaluate the fip at additional times e.g. during model evaluation we
can use the conditional GP framework and treat the observed values as pseudo-inputs, from
the sparse GP literature (Titsias (2009)). Finally, for all model parameters Θ we learn a
point estimate, so that their variational distributions are delta functions. We impose vague
normal priors on Λ(p), β(p), and W , a uniform prior on Ψ(p), and simply learn MLEs for
other parameters. Thus, the goal of our variational algorithm is to learn optimal variational
parameters λi = {νci , νzip , µbi ,Σbi , µfip ,Σfip} for each individual i, as well as a point estimate
Θˆ for the model parameters. In practice, we optimize the Cholesky decompositions of
covariance matrices.
Solving the Optimization Problem
We use the automatic differentiation package autograd 1 in Python to compute analytic
gradients in order to optimize the lower bound, since the lower bound has an analytic
expression. At each iteration of the algorithm, we optimize the local variational parameters
using exact gradients. To optimize the global parameters, we turn to stochastic optimization,
a commonly used tool in variational inference. Rather than using the entire large dataset
to compute exact gradients of the ELBO with respect to Θ, we can compute an unbiased
noisy gradient based on a sampled batch of observations (Hoffman et al. (2013)). To set the
learning rate we use RMSProp, which adaptively allows for a different learning rate for each
parameter (Tieleman and Hinton (2012)).
5. Empirical Study
In this section we describe our experimental setup and results on our dataset.
Dataset
Our dataset contains laboratory values from 44,519 patients with stage 3 CKD or higher
extracted from the Duke University Health System EHR. IRB approval (#Pro00066690)
was obtained for this work. We first created an initial cohort of roughly 600,000 patients
that had at least one encounter in the health system in the year prior to Feb. 1, 2015. This
includes all types of encounters within the health system, including inpatient, outpatient,
and emergency department visits, over a span of roughly 20 years. From this, we filtered
to patients who had at least five recorded values for serum creatinine, the laboratory value
we used to calculate eGFR. We next filtered to patients that had Stage 3 CKD or higher,
1. https://github.com/HIPS/autograd
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indicative of moderate to severe kidney damage, defined as two eGFR measurements less
than 60 mL/min separated by at least 90 days.
We also choose to model five related lab values that have important clinical significance
for CKD. The first, Serum Albumin, is an overall marker of health and nutrition. The second,
Serum Bicarbonate, can indicate acid accumulation from inadequate acid elimination by the
kidney. The third, Serum Calcium, can indicate improperly functioning kidneys if levels
are too high. The fourth, Serum Phosphorus, can indicate phosphorus accumulation due to
inadequate elimination by the kidney, and is associated with cardiovascular death and bone
disorders. Finally, Urine Albumin to Creatinine Ratio (ACR) is a risk factor and cause of
kidney failure. While all 44,519 patients have at least five eGFR measurements, there are
884, 242, 78, 16159, and 4321 patients who have no recorded values for the other five labs,
respectively. The median number of measurements for each lab (among patients with at
least one) is 14, 8, 11, 12, 3, and 4, respectively.
As a final preprocessing step, since the recorded eGFR values are extremely noisy and
eGFR is only a valid estimate of kidney function at steady state, we take the mean of eGFR
readings in monthly time bins for each patient. Rapid fluctuations in acute illness are related
to long term risk, but we have not yet explicitly incorporated this into our modeling. We
also do this to the other lab values, to reduce the overall noise in short time spans when
there may be many rapidly changing measurements. In order to align the patients on a
common time axis, for each patient we fix t = 0 to be their first recorded eGFR reading
below 60 mL/min. The baseline covariates used for xi were baseline age, race and gender,
and indicator variables for hypertension and diabetes, as well as an overall intercept.
Evaluation
After learning a point estimate for the global model parameters during training, they are
held fixed. Then, an approximate posterior over the local latent variables is learned for each
patient in the held-out test set. Predictions about future lab values are made by drawing
samples from the approximate posterior predictive. We compare our method with the method
of (Schulam and Saria (2015)), trained independently to each of the 6 labs. We use 10 fold
cross validation and use one-sided, paired t-tests to test for significant improvements in
performance. For each test patient, we learn their parameters using their data up until time
t = 1, t = 2, and t = 4, and record the mean absolute error of the predictions for each lab in
future time bins. These values are then averaged over all patients in the test set, and finally
averaged over the 10 cross validation folds to produce Table 1.
Results
Table 1 displays the results of both methods. Our proposed method outperforms (Schulam
and Saria (2015)) for labs that had higher amounts of missingness. In these settings, the
methods sometimes have to predict held-out lab values for a patient without having yet
observed any values for that lab. In this case (Schulam and Saria (2015)) can only predict
using baseline covariates for that individual, while our multivariate approach is able to
leverage information from the other related labs as well. Interestingly, our method performs
slightly worse at predicting eGFR, perhaps because this is the most commonly measured
variable in our cohort. Current clinical practice for managing care of CKD patients does not
8
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Table 1: Mean Absolute Errors across all labs from 10 fold cross validation. Bold indicates p-
value from one-sided, paired t-test comparing methods was < .05. *,**,*** indicate
p < .01, < .001, < .0001, respectively.
Predictions with data up to... t = 1 t = 2 t = 4
Lab Model (1, 2] (2, 4] (4, 8] (8, 19] (2, 4] (4, 8] (8, 19] (4, 8] (8, 19]
eGFR Schulam 8.86* 10.43* 12.05 13.69 8.84*** 11.08** 13.23* 9.39*** 12.29*
Proposed 9.12 10.67 12.28 14.21 9.26 11.73 13.99 10.12 13.07
Serum Alb. Schulam 0.59 0.79 1.09 1.53 0.60 0.88 1.28 0.63 0.96
Proposed 0.34*** 0.39*** 0.47*** 0.63*** 0.35*** 0.45*** 0.63*** 0.40*** 0.58***
Serum Bicarb. Schulam 1.92 2.06 2.13 2.31 1.93 2.06 2.21 1.89 2.14
Proposed 1.87 1.97 2.04 2.31 1.89 1.99 2.31 1.87 2.24
Serum Calc. Schulam 0.74 1.02 1.62 2.89 0.72 1.26 2.27 0.85 1.53
Proposed 0.37*** 0.44*** 0.58*** 0.80*** 0.39*** 0.54*** 0.80*** 0.46*** 0.73***
Serum Phos. Schulam 1.02 1.35 1.46 1.44 1.17 1.36 1.34 1.13 1.15
Proposed 0.57*** 0.68*** 0.88*** 1.23 0.65*** 0.88*** 1.25 0.82*** 1.23
Urine ACR Schulam 1.17 1.30 1.44 1.64 1.14 1.30 1.53 1.11 1.41
Proposed 0.92*** 1.02*** 1.17*** 1.44 0.96*** 1.13* 1.45 1.02 1.42
use any form of modeling to predict future disease status or lab values. Incorporation of a
model such as ours to predict future eGFR trajectory and other labs would provide a useful
tool for nephrologists to assess the risk of future decline in kidney function in CKD patients.
6. Discussion
In this paper, we proposed a flexible model for multivariate longitudinal data, and applied it
to disease trajectory modeling in CKD patients. We find our model yields good performance
on the task of predicting future kidney function and related lab values. Although our work is
a promising first step for developing machine learning models from EHR data and applying
them to real clinical tasks, many inherent limitations to working with operational EHR data
(Hersh and et al (2013)) must be overcome in order for the methods to be used in practice.
There are many interesting directions for extending the ideas presented here. We plan to
consider models for other diseases, including diabetes and cardiovascular disease, which are
frequently comorbid with CKD. Incorporation of a larger number of longitudinal variables
will require care in order to ensure tractability, especially if we choose to model vitals that
are recorded much more frequently. Another interesting direction to consider is joint models
for adverse event data, such as in (Futoma et al. (2016)). Jointly modeling multiple event
processes (e.g. emergency department visits, heart attacks, strokes) will allow us to learn
correlations between different types of events. Given that much of the data recorded in the
EHR is in the form of administrative billing codes, future work should incorporate these into
the models as well. Finally, models incorporating additional outcomes such as medical costs,
hospitalizations, and patient quality of life are of significant practical interest.
The screenshot in Figure 2 shows a working prototype of the application being developed
in collaboration with Duke Connected Care, where we use our predictions to help flag high
risk patients for chart review during weekly rounding sessions. By further refining and
deploying a flexible, scalable predictive tool such as ours, ACOs around the country can
intervene on high-risk patients and realize the potential benefits of precision medicine.
Acknowledgments
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Figure 2: Snapshots from our CKD rounding application (with synthetic data). The top
panel shows a pre-rounding table of patients to be rounded on, along with risk
scores and appropriate flags. The middle panel displays patient data and other
relevant information so that this patient’s care can be efficiently managed and an
appropriate intervention made, if applicable. The bottom panel shows a list of
tasks assigned to each group present at rounds.
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